A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
June 17 (Reuters) – Bristol-Myers Squibb Co (BMY.N) and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.
Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.
They would jointly develop and market the drug, MORAb-202, in Asia, Europe, the United States and Canada.
Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc (AGEN.O) to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.
The drugmaker has been betting on sales of its Opdivo drug to treat such cancers, in a market currently dominated by Merck & Co’s (MRK.N) rival treatment, Keytruda.
Eisai’s drug, MORAb-202, is being developed for the treatment of solid tumors, including ovarian, lung and breast cancers and is in the early stage of development.
Bristol-Myers will pay Eisai a royalty on sales outside of the collaboration territories, the companies said.Reporting by Amruta Khandekar; Editing by Vinay Dwivedi
Our Standards: The Thomson Reuters Trust Principles.
Global Fashion Agenda has revealed Building Resilient Futures as the theme for the Global Fashion…
The Electricity Connect 2025 conference in Jakarta spotlighted Indonesia’s energy transition, with Huawei recognised as…
After years of material science breakthroughs, a team proved that a rugged, sea-ready composite could…
TAHO, a Venice-based compute startup founded by ex-Meta and Google engineers, raised $3.5 million in…
The 9th Future Investment Initiative in Riyadh spotlighted how AI is rapidly redefining global growth,…
Onward Robotics has appointed Brendon Bielat as Chief Product Officer, strengthening its leadership team as…